Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 7/2007

01-07-2007 | Case Report

The dynamism of cutaneous lupus erythematosus: mild discoid lupus erythematosus evolving into SLE with SCLE and treatment-resistant lupus panniculitis

Authors: Anna Wozniacka, Małgorzata Salamon, Aleksandra Lesiak, Daniel Paul McCauliffe, Anna Sysa-Jedrzejowska

Published in: Clinical Rheumatology | Issue 7/2007

Login to get access

Abstract

We present a 47-year-old Caucasian female who initially presented with mild discoid lupus erythematosus that evolved into systemic lupus erythematosus with subacute cutaneous LE and treatment-recalcitrant lupus panniculitis. Conventional therapy with antimalarials, systemic steroids, azathioprine, cyclophosphamide, methotrexate, and pulse doses of methylprednisolone did not control the course of the disease. Cyclosporin-A treatment led to clinical improvement and maintained remission.
Literature
1.
Gilliam JN, Sontheimer RD (1981) Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 4:471–475PubMedCrossRef
2.
Irgang S (1940) Lupus erythematosus profundus. Report of an example with clinical resemblance to Darier–Roussy sarcoid. Arch Dermatol Syph 42:97–108
3.
Tuffanelli DL (1982) Lupus erythematosus (panniculitis) profundus: a classic revisited commentary and report of 22 cases. Hawaii Med J 41:394–397PubMed
4.
5.
Jordan DR, McDonald H, Olberg B et al (1993) Orbital panniculitis as the initial manifestation of systemic lupus erythematosus. Ophthal Plast Reconstr Surg 9:71–75PubMedCrossRef
6.
Nowinski T, Bernardino V, Naidoff M et al (1982) Ocular involvement in lupus erythematosus profundus (panniculitis). Ophthalmology 89:1149–1154PubMed
7.
Tada J, Arata J, Katayama H (1991) Linear lupus erythematosus profundus in a child. J Am Acad Dermatol 24:871–874PubMed
8.
9.
Macjejewski W, Bandmann HJ (1979) Lupus erythematosus panniculitis (profoundus). Acta Derm Venereol Suppl (Stockh) 59:109–112
10.
Fox JN, Klapman MH, Rowe L (1987) Lupus profundus in children: treatment with hydroxychloroquine. J Am Acad Dermatol 16:839–844PubMed
11.
Chung HS, Hann SK (1997) Lupus panniculitis treated by combination therapy of hydroxychloroquine and quinacrine. J Dermatol 24:569–572PubMed
12.
Martens PB, Moder KG, Ahmed L (1999) Lupus panniculitis: clinical perspectives from a case series. J Rheumatol 26:68–72PubMed
13.
Khalfallah N, Azzabi S, Ben Hassine L et al (2003) Cutaneous lupus profundus. Tunis Med 81:134–139PubMed
14.
Wimmershoff MB, Hohenleutner U, Landthaler M (2003) Discoid lupus erythematosus and lupus profundus in childhood: a report of two cases. Pediatr Dermatol 20:140–145PubMed
15.
Yell JA, Burge SM (1993) Lupus erythematosus profundus treated with clobetasol propionate under a hydrocolloid dressing. Br J Dermatol 128:103PubMedCrossRef
16.
Inuzuka M, Tomita K, Tokura Y, Takigawa M (2001) Lupus erythematosus profundus with unusual skin manifestation: subcutaneous nodules coexisting with eyelid plaques. J Dermatol 28:437–441PubMed
17.
Morgan KW, Callen JP (2001) Calcifying lupus panniculitis in patients with subacute cutaneous lupus erythematosus: response to diltiazem and chloroquine. J Rheumatol 28:129–132
18.
Yamada Y, Dekio S, Jidoi J, Ozasa S (1989) Lupus erythematosus profundus—report of a case treated with dapson. J Dermatol 16:379–382PubMed
19.
Bohm I, Burns A, Schupp G, Bauer R (1998) ANCA-positive lupus erythematodes profundus. Successful therapy with low dosage dapson. Hautarzt 49:403–407PubMedCrossRef
20.
21.
Burrows NP, Walport MJ, Hammond AH et al (1991) Lupus erythematosus profundus with partial C4 deficiency responding to thalidomide. Br J Dermatol 125:62–67PubMedCrossRef
22.
Peters MS, Su WP (1989) Lupus erythematosus panniculitis. Med Clin North Am 73:1113–1126PubMed
23.
Wang SW, Cheng TT (2005) Systemic lupus erythematosus with refractory hemolytic anemia effectively treated with cyclosporin A: a case report. Lupus 14:483–485PubMedCrossRef
24.
Saeki Y, Ohshima S, Kurimoto I et al (2000) Mainataining remission of lupus erythematosus profundus (LEP) with cyclosporin A. Lupus 9:390–392PubMedCrossRef
25.
26.
Hytiroglou P, Phelps RG, Wattenberg DJ et al (1992) Cytophagic histiocytic panniculitis; Molecular evidence for a clonal T cell disorder. J Am Acad Dermatol 27:333–336PubMedCrossRef
27.
Furman DA, Klee CB, Bievier BE, Burakoff SJ (1990) Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci USA 89:3686–3690CrossRef
Metadata
Title
The dynamism of cutaneous lupus erythematosus: mild discoid lupus erythematosus evolving into SLE with SCLE and treatment-resistant lupus panniculitis
Authors
Anna Wozniacka
Małgorzata Salamon
Aleksandra Lesiak
Daniel Paul McCauliffe
Anna Sysa-Jedrzejowska
Publication date
01-07-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 7/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0310-6

Other articles of this Issue 7/2007

Clinical Rheumatology 7/2007 Go to the issue

Case Report

Scalp necrosis: a rare complication of temporal arteritis

Brief Report

Osteoporosis in men: are we referring enough for DXA and how?

Brief Report

Meta-analysis is no substitute for a comprehensive national registry

Case Report

Successful treatment of refractory rash in paraneoplastic amyopathic dermatomyositis

Original Article

A follow-up study of minimally invasive lip biopsy in the diagnosis of Sjögren’s syndrome

Original Article

Ten years of clinical experience with adult onset Still’s disease: is the outcome improving?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits